The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC.
Katsuyuki Kiura
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Takashi Seto
Honoraria - Chugai Pharma
Nobuyuki Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Makoto Nishio
Honoraria - Chugai Pharma
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Tomohide Tamura
Honoraria - Chugai Pharma